Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer

Medicine & Life Sciences

• human ERBB2 protein 100%
• Trastuzumab 60%
• Breast Neoplasms 52%
• Anthracyclines 23%
• United States Food and Drug Administration 20%
• Drug Therapy 17%
• N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 17%
• Ado-Trastuzumab Emtansine 16%
• pertuzumab 15%
• Lapatinib 14%
• Drug Approval 13%
• Capecitabine 12%
• Survival 11%
• Adjuvant Chemotherapy 10%
• Combination Drug Therapy 10%
• Drug Delivery Systems 10%
• Protein-Tyrosine Kinases 9%
• Survival Rate 7%
• Monoclonal Antibodies 7%
• Safety 5%
• Pharmaceutical Preparations 4%
• Neoplasms 3%
• Therapeutics 1%

Chemical Compounds

• Adjuvant 50%
• Neratinib 20%
• Lapatinib 17%
• Capecitabine 17%
• Tyrosine Kinase Inhibitor 14%
• Drug 10%
• Safety 8%
• Molecule 3%